Posted by Michael Wonder on 02 Oct 2025
Wockhardt submits new drug application to US FDA for zidebactam-cefepime (WCK 5222) for treatment of serious gram-negative infections
1 October 2025 - Wockhardt today announced the submission of new drug application to the US FDA for its novel antibacterial agent zidebactam-cefepime injection (WCK 5222, Zaynich).
The new drug application seeks approval for the treatment of complicated urinary tract infections, including pyelonephritis, with or without concurrent bacteraemia caused by Gram negative bacteria including multi drug-resistant.
